What is Helex?
Helex, established in 2021 and headquartered in New York, New York, is at the forefront of biotechnology innovation, specifically targeting kidney diseases through advanced genomic medicines. The company leverages its proprietary lipid nanoparticle technology for precise delivery to the kidney, coupled with its Epic-Cure technology platform. This platform utilizes data-driven deep-learning modeling to design and validate guide RNAs for CRISPR-based gene editing, enabling highly accurate drug design by predicting edit outcomes and ensuring safety by avoiding off-target edits. Helex's therapeutic pipeline is dedicated to addressing conditions such as Autosomal Dominant Polycystic Kidney Disease, reflecting a commitment to developing novel therapies for patients suffering from chronic kidney disease.
How much funding has Helex raised?
Helex has raised a total of $3.5M across 1 funding round:
Seed
$3.5M
Seed (2025): $3.5M with participation from Pi Ventures
Key Investors in Helex
Pi Ventures
Pi Ventures is a venture capital firm founded in 2016, based in Bangalore, India, with a focus on companies developing artificial intelligence, machine learning, and IoT technologies.
What's next for Helex?
With the recent major strategic investment, Helex is poised for significant expansion in its research and development efforts. The substantial backing provides the necessary capital to advance its proprietary technologies and accelerate the clinical development of its gene editing therapeutics for kidney diseases. This funding round is indicative of Helex's transition into a scaling phase, enabling the company to further validate its platform and potentially broaden its therapeutic focus within the renal indication space, solidifying its position as a key player in the biotechnology sector.
See full Helex company page
